5-Alpha Reductase Inhibitor (5ARI) – Boston Collaborative Drug Surveillance Program (BCDSP)

The risk of venous thromboembolism (VTE) in men with benign prostatic hyperplasia treated with 5-Alpha Reductase Inhibitors (5ARIs)

By BCDSP August 3, 20215-Alpha Reductase Inhibitor (5ARI), PhD Studies, Select Publications, Student Studies, Venous Thromboembolism (VTE)

Journal: Clinical Epidemiology Authors: Olulade Ayodele, Howard J Cabral, David McManus, Susan Jick NLM Citation: Ayodele O, Cabral HJ, McManus D, Jick S. The Risk of Venous Thromboembolism (VTE) in Men with Benign…